Impact Biomedical Inc. (IBO)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $4.10
- As of
Kresmion compiles this page from IBO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
IMPACT BIOMEDICAL INC. (IBO): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-03.
See the full IBO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IBO on one page. Preview it with sample data, then open it live with a free account.
Preview the IBO dossierActive events for IBO
- medium13F: new position
CITADEL ADVISORS LLC new position in IBO
- high13F: large reduction
TWO SIGMA INVESTMENTS, LP cut 54% of IBO (2026Q2)
FREE, NO ACCOUNT
Every event on IBO, as it fires
New filings, 13F moves and cross asset events on IBO land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
IBO positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| CITADEL ADVISORS LLC FundCUSIP 45259L205 · 2026Q2 | $23K | 0.00% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 45259L205 · 2026Q2 | $8K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IBO
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
IBO's 10-Q filed Aug 7, 2026 states:
These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on IBO
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in IBO on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on IBO in the last 180 days.
Upstream: SEC EDGAR filings for IBO
Kresmion, "IMPACT BIOMEDICAL INC. (IBO) institutional holdings and SEC filings", data as of 2026-11-03, https://kresmion.com/research/IBO. Upstream data: SEC EDGAR filings for IBO.
Link to this data (HTML):
<a href="https://kresmion.com/research/IBO">IMPACT BIOMEDICAL INC. (IBO) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow IBO on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to IBO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.